Daxor

DXR · NASDAQ

$9.75−$0.09 (−0.91%)TodayMarket closed ·
Prev close $9.84

About DXR

Daxor Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. The company specializes in blood volume measurement technology focused on blood volume testing innovation. The company markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. The company has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Employees
0
Headquarters
Oak Ridge, Tennessee
Listed
Jul 25, 1983
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
daxor.com

DXR key statistics

Market cap
61.48M
Price-earnings ratio
5.43
Dividend yield
—
Average volume
15.52K
Volume
2.84K
Open price
$9.80
High today
$10.04
Low today
$9.70
52 Week high
$14.76
52 Week low
$8.56

Daxor (DXR) at a glance

As of Oct 20, 2026, Daxor (DXR) shares are priced at $9.75, giving the company a market cap of 61.48M and a price-to-earnings ratio of 5.43.

Today the stock has traded between $9.70 and $10.04. The current price is 0.5% above the day's low and 2.9% below its high.

Volume so far is 2.84K shares, below the average of 15.52K shares a day.

Over the past year Daxor has ranged from $8.56 to $14.76, and now sits 19% of the way up that range.

Daxor met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY07 it reported $0.43 per share against an estimate of $0.101.

DXR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 1321.8% on average.

  1. Q4 FY05: reported -$0.19 per share against an estimate of -$0.1111
  2. Q1 FY06: reported -$0.01 per share against an estimate of -$0.1111
  3. Q2 FY06: reported $0.03 per share against an estimate of -$0.0808
  4. Q3 FY06: reported -$0.20 per share against an estimate of -$0.0202
  5. Q4 FY06: reported $0.01 per share against an estimate of -$0.0202
  6. Q1 FY07: reported $0.66 per share against an estimate of -$0.0303
  7. Q2 FY07: reported $0.51 per share against an estimate of $0.0101
  8. Q3 FY07: reported $0.43 per share against an estimate of $0.101

DXR news

  • Press releaseGlobe Newswire

    Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26

  • Press releaseGlobe Newswire

    Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026

  • Press releaseGlobe Newswire

    Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026

  • Press releaseGlobe Newswire

    Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026

  • Press releaseGlobe Newswire

    Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

  • Press releaseGlobe Newswire

    Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

  • Press releaseGlobe Newswire

    Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

  • Press releaseGlobe Newswire

    Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.